Substance P release after traumatic brain injury and stroke drives blood-brain barrier breakdown and brain swelling, and blocking it with NK1 receptor antagonists reduces damage with a therapeutic window of up to 12 hours.
12-hour therapeutic windowNK1 receptor antagonists that block Substance P showed benefits in animal models of brain injury even when administered up to 12 hours after the insult — a clinically practical timeframe for emergency treatment.
What the researchers found
Substance P expression increases after acute CNS injury, with the magnitude of release correlating to both the frequency and severity of the insult. SP release directly promotes blood-brain barrier permeability, vasogenic edema formation, neuronal injury, and worse functional outcomes.
NK1 receptor antagonists that block Substance P's actions showed high therapeutic benefit in both focal and diffuse models of traumatic brain injury, as well as in ischemic stroke models. The therapeutic window extends up to 12 hours post-injury, making this a potentially practical intervention for emergency medicine settings.
Why it matters
There are no effective drug treatments for the secondary brain damage that occurs after traumatic brain injury or stroke. Identifying Substance P as a key driver of this damage, and showing that blocking it with existing drug classes works within a 12-hour window, points to a realistic new therapeutic strategy. NK1 receptor antagonists already exist (some are approved for other uses like anti-nausea), which could accelerate clinical development.
How the study worked
This is a narrative review synthesizing published preclinical research on neurogenic inflammation after acute CNS injury. The authors reviewed evidence from animal models of focal and diffuse traumatic brain injury and ischemic stroke, focusing on Substance P release patterns, blood-brain barrier changes, edema formation, and the effects of NK1 receptor antagonist treatment.
What this study cannot tell us
This is a review article based primarily on preclinical animal model data. No human clinical trial data are presented. The 12-hour therapeutic window was demonstrated in animal models and may differ in humans. The translation from rodent brain injury models to human TBI and stroke is notoriously challenging. Long-term safety and efficacy of NK1 receptor antagonists in CNS injury patients are unknown.
How to read the evidence
This is a narrative review of preclinical animal studies. The evidence from multiple injury models is consistent and compelling, but no human clinical data exist. The translation from animal models of brain injury to clinical outcomes is historically difficult.
When this study was published
Published in 2016 in the British Journal of Pharmacology, this review synthesized an emerging body of evidence on neurogenic inflammation. Subsequent research has continued to explore NK1 antagonists in neurotrauma.
The bigger picture
Neurogenic inflammation — driven by neuropeptides like Substance P — is emerging as a major contributor to secondary brain injury. This paradigm shift from traditional immune-mediated inflammation to neuropeptide-driven processes opens new therapeutic avenues. The ability to target Substance P with NK1 receptor antagonists, some of which are already clinically available, makes this one of the more translatable neurotrauma research findings.
Questions still open
- Will NK1 receptor antagonists show the same benefit in human traumatic brain injury and stroke patients?
- Could existing approved NK1 antagonists (like aprepitant) be rapidly repurposed for acute CNS injury?
- Is the 12-hour therapeutic window clinically practical for emergency treatment of TBI and stroke?
Common questions
What is Substance P and why does it cause damage after brain injury?
Could anti-nausea drugs be used to treat brain injury?
Read the original research
Inflammation in acute CNS injury: a focus on the role of substance P.
British journal of pharmacology, 173(4), 703-15
Citation
Corrigan, F; Vink, R; Turner, R J. (2016). Inflammation in acute CNS injury: a focus on the role of substance P.. British journal of pharmacology, 173(4), 703-15. https://doi.org/10.1111/bph.13155